Refine by
Cytomx Preclinical Study Equipment & Supplies
2 equipment items found
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
As with anti-PD-L1 therapies, PD-1 monotherapy and combinations have been associated with significant toxicities. Our preclinical studies have shown that CX-188 has the potential for an improved therapeutic index relative to PD-1 antibodies. The IND for CX-188 was cleared by the FDA. Following a program and portfolio prioritization, CytomX has decided to ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CD166 is a molecule widely and highly expressed on solid tumor cells and previously considered “undruggable” given its expression on normal tissues. In preclinical studies, Probody drug conjugates targeting CD166, have led to complete regressions in models of breast and lung cancer at therapeutically relevant doses, and are well tolerated in non-human ...